Royalty pharma plc RPRX 深 滬
等待開盤 12-12 09:30:00 美东时间
38.81
+0.550
+1.44%
華盛通- 最 高38.81
- 今 開38.30
- 成交量 409.04万股
- 最 低 37.935
- 昨 收 38.26
- 總市值 163.39亿
- 52周最高 41.02
- 市盈率 靜 20.30
- 換手率 0.97%
- 52周最低 23.58
- 委 比 -84.44%
- 總股本 4.21亿
- 歷史最高 52.24
- 量 比 0.74
- 振 幅 2.29%
- 歷史最低 23.17
- 每 手 1
- 風險率 3.77%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 绩后分化！甲骨文遭14家大行集体下调目标价；新思科技、Planet获多家机构上调目标价！
今日重点评级关注：HC Wainwright & Co.：维持Moleculin Biotech"买入"评级，目标价从4美元升至22美元；HC Wainwright & Co.：上调Soluna Holdings评级至"买入"，目标价5美元
今天 10:24
TD Cowen Maintains Buy on Royalty Pharma, Raises Price Target to $45
TD Cowen analyst Steve Scala maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the price target from $42 to $45.
今天 00:29
Denali Flags Minimal Delay After FDA Halts Rare Disease Trial Start
FDA placed hold on Denali's drug for Pompe disease, requesting changes to protocol. No additional studies requested. Minimal delays expected.
12-06 00:49
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement
Denali Therapeutics and Royalty Pharma have entered a $275 million synthetic royalty agreement for tividenofusp alfa, Denali’s enzyme replacement therapy for Hunter syndrome. The FDA is reviewing its BLA for accelerated approval, with a PDUFA date of April 5, 2026. Royalty Pharma will pay $200 million upfront and $75 million upon EMA approval by 2029, receiving a 9.25% royalty on global sales.
12-04 12:00
Is Royalty Pharma PLC Gaining or Losing Market Support?
Royalty Pharma PLC's (NYSE:RPRX) short interest as a percent of float has risen...
11-28 04:00
Royalty Pharma to Present at Upcoming Investor Conferences
Royalty Pharma plc (Nasdaq: RPRX) will participate in two investor conferences in December: Citi’s 2025 Global Healthcare Conference on December 2 at 3:15 p.m. ET and Evercore’s 8th Annual Healthcare Conference on December 3 at 3:50 p.m. ET. A live webcast will be available on Royalty Pharma’s “Events” page, with an archive for 30 days. Founded in 1996, Royalty Pharma is the largest purchaser of biopharmaceutical royalties and a key innovator in ...
11-26 13:15
OSR Holdings' Vaximm Enters Into Non-Binding Term Sheet With BCM Europe To Explore Potential Exclusive Global Licensing Agreement For VXM01, Oral Cancer Immunotherapy Platform
OSR Holdings, Inc. (NASDAQ:OSRH), today announced that Vaximm AG, an OSR Company, has entered into a non-binding term sheet with BCM Europe AG ("BCME"), a Swiss-based life sciences investment group and OSRH's largest
11-21 22:25
美股盘后 | 安森美半导体涨3.16%，Constellation Energy Group Inc.涨2.55%
安森美半导体涨3.16%；Constellation Energy Group Inc.涨2.55%；Fortress Transportation & Infrastructure Investors LLC涨2.00%
11-19 07:11
美股盘后 | 思科涨7.49%，Revolution Medicines涨3.30%
思科涨7.49%；Revolution Medicines涨3.30%；Royalty pharma plc涨2.85%
11-13 07:11
Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Zenas BioPharma reported positive Phase 2 results for obexelimab in relapsing MS, demonstrating a 95% reduction in gadolinium-enhancing lesions vs. placebo. The company also expects to report Phase 3 data for obexelimab in IgG4-RD by year-end 2025. Zenas secured rights to orelabrutinib, a BTK inhibitor in Phase 3 for progressive MS, and entered a $300M funding agreement with Royalty Pharma. They completed a $120M private placement and reported $3...
11-12 12:05
